Immunocore (NASDAQ:IMCR) CEO Bahija Jallal Sells 11,474 Shares

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) CEO Bahija Jallal sold 11,474 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $371,183.90. Following the transaction, the chief executive officer directly owned 12,343 shares of the company’s stock, valued at $399,296.05. This trade represents a 48.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Immunocore Price Performance

Shares of Immunocore stock traded up $0.66 during trading on Thursday, reaching $33.17. 392,220 shares of the stock traded hands, compared to its average volume of 465,558. Immunocore Holdings PLC Sponsored ADR has a 52-week low of $23.15 and a 52-week high of $40.71. The company has a debt-to-equity ratio of 0.99, a current ratio of 6.00 and a quick ratio of 5.97. The business has a fifty day simple moving average of $33.94 and a two-hundred day simple moving average of $34.31. The company has a market capitalization of $1.68 billion, a price-to-earnings ratio of -58.19 and a beta of 0.78.

Institutional Trading of Immunocore

Institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada increased its position in Immunocore by 45.1% during the first quarter. Royal Bank of Canada now owns 44,011 shares of the company’s stock valued at $1,306,000 after acquiring an additional 13,689 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Immunocore by 4,696.3% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 1,295 shares of the company’s stock worth $41,000 after purchasing an additional 1,268 shares during the period. State of New Jersey Common Pension Fund D purchased a new position in shares of Immunocore during the 2nd quarter worth about $292,000. Y Intercept Hong Kong Ltd bought a new position in Immunocore during the 2nd quarter valued at about $1,621,000. Finally, Assetmark Inc. raised its position in Immunocore by 3.7% in the 2nd quarter. Assetmark Inc. now owns 34,958 shares of the company’s stock worth $1,097,000 after purchasing an additional 1,248 shares during the period. 84.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

IMCR has been the topic of a number of research reports. Zacks Research raised Immunocore from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 7th. Morgan Stanley raised their target price on shares of Immunocore from $34.00 to $36.00 and gave the company an “equal weight” rating in a report on Monday, November 10th. Mizuho set a $38.00 price target on shares of Immunocore in a research report on Thursday. UBS Group set a $55.00 price objective on shares of Immunocore and gave the company a “buy” rating in a research report on Wednesday, January 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research note on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.90.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.